In 2024, Johnson & Johnson’s net earnings were estimated to be about 14 billion U.S. dollars. This is a significant decrease compared to the previous year, when net earnings stood at about 35 billion U.S. dollars. Johnson & Johnson’s revenue overview Johnson & Johnson is a U.S.-based multinational company that is headquartered in New Brunswick, New Jersey, in the United States. The company’s largest business segment is their pharmaceutical segment, but the company also operates in medical devices and diagnostics. Regionally, the United States is responsible for the largest proportion of Johnson & Johnson’s sales, followed by Europe. Johnson & Johnson’s global R&D positioning Johnson & Johnson has been ranked second among global pharmaceutical companies based on their dollar amount spent on research and development in 2023. Johnson & Johnson is ranked among the top 10 pharmaceutical companies based on the number of originated drugs. Similarly, Johnson & Johnson is ranked among the top seven pharmaceutical companies based on the number of drugs in development as of 2024.

J&J reported $5.54B in Net Income for its fiscal quarter ending in June of 2025. Data for J&J | JNJ - Net Income including historical, tables and charts were last updated by Trading Economics this last September in 2025.

The net income of Johnson & Johnson with headquarters in the United States amounted to ***** billion U.S. dollars in 2014. The reported fiscal year ends on December 29.Compared to the earliest depicted value from 2010 this is a total increase by approximately **** billion U.S. dollars. The trend from 2010 to 2014 shows, however, that this increase did not happen continuously.

This statistic shows the total revenue of Johnson & Johnson worldwide from 2012 to 2024. Johnson & Johnson is a multinational company, specialized on pharmaceuticals, medical devices and consumer goods. The company is headquartered in New Brunswick, New Jersey. In 2018, Johnson & Johnson's global revenue is estimated to amount to about 78.27 billion U.S. dollars.

Johnson & Johnson's annual net income per employee was $101.85 K in fiscal year 2024. The net income per employeedecreased$128.36 Kfrom $230.21 K(in 2023) to $101.85 K (in 2024), representing a -55.76% year-over-year decline.

Net-Profit-Margin Time Series for Johnson & Johnson. Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson Controls reported $701M in Net Income for its fiscal quarter ending in June of 2025. Data for Johnson Controls | JCI - Net Income including historical, tables and charts were last updated by Trading Economics this last September in 2025.

In 2024, Johnson & Johnson's generated approximately ** billion U.S. dollars in sales. This statistic shows the global total sales of Johnson & Johnson from 2005 to 2024. Johnson & Johnson is a multinational company, specialized in pharmaceuticals, medical devices, and consumer goods. The company is headquartered in New Brunswick, New Jersey. Johnson & Johnson’s global position Johnson & Johnson has been ranked among the top pharmaceutical companies globally recently and in multiple categories. As of 2024, it was the leading pharmaceutical company worldwide in terms of total revenue generated. Furthermore, Johnson and Johnson was also the leading pharmaceutical company globally by prescription sales revenue in 2023, as well as being the second ranked company worldwide in terms of its research and development spending. Johnson & Johnson’s research and development Johnson and Johnson’s research and development expenditure has been steadily and gradually increasing in the past five years. In 2024, the company spent over ** billion U.S. dollars on research and development, accounting for some ** percent of total sales that year.

The net income of Johnson Service Group with headquarters in the United Kingdom amounted to ************ British pounds in 2023. The reported fiscal year ends on December 31.Compared to 2020, this marks an increase of approximately ********** British pounds. The trend from 2020 to 2023 shows, however, that this increase did not happen continuously.

Net-Income-Including-Non-Controlling-Interests Time Series for Johnson Controls International PLC. Johnson Controls International plc, together with its subsidiaries, engages in engineering, manufacturing, commissioning, and retrofitting building products and systems in the United States, Europe, the Asia Pacific, and internationally. It operates through four segments: Building Solutions North America, Building Solutions EMEA/LA, Building Solutions Asia Pacific, and Global Products. The company designs, sells, installs, and services heating, ventilating, air conditioning, controls, building management, refrigeration, integrated electronic security, integrated fire detection and suppression systems, and fire protection and security products. It also provides energy efficiency solutions and technical services, including inspection, scheduled maintenance, and repair and replacement of mechanical and control systems, as well as data-driven smart building solutions. In addition, the company offers control software and software services. It sells its products and services to commercial, institutional, industrial, data center, and governmental customers. Johnson Controls International plc was incorporated in 1885 and is headquartered in Cork, Ireland.

Johnson Matthey reported GBP-111M in Net Income for its fiscal semester ending in June of 2025. Data for Johnson Matthey | JMAT - Net Income including historical, tables and charts were last updated by Trading Economics this last September in 2025.

Total-Other-Income-Expense-Net Time Series for Johnson & Johnson. Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

The net income of Johnson Health Tech. with headquarters in Taiwan amounted to ****** million New Taiwan dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2019 this is a total decrease by approximately ****** million New Taiwan dollars. The trend from 2019 to 2023 shows, however, that this decrease did not happen continuously.

In 2018, Johnson & Johnson generated over 12 billion U.S. dollars in revenue through immunology products. Revenue from this product category is projected to decrease in the coming years, while earnings from the oncology category are set to increase.

Johnson & Johnson’s total revenue

Johnson & Johnson’s global revenue came to some 82 billion U.S. dollars in 2019 – although this is the total revenue from all three of the company’s segments. Over the past decade, the company’s total revenue numbers have increased by almost 22 percent. The multinational, headquartered in New Jersey, earns roughly half of that revenue in its home market: in 2018, J&J generated close to 42 billion U.S. dollars in the United States. A total of approximately 15 billion U.S. dollars were made in the African and Asian Pacific regions that year.

J&J WORKFORCE

In 2017, J&J’s workforce count had, for the first time, reached and exceeded the 130 thousand mark. In 2018 specifically, just over 135 thousand people worked for Johnson & Johnson. These employees are active in various areas in over 60 countries worldwide: from pharmaceutical R&D to manufacturing and sales.

Johnson Outdoors reported $-34.27M in Net Income for its fiscal quarter ending in September of 2024. Data for Johnson Outdoors | JOUT - Net Income including historical, tables and charts were last updated by Trading Economics this last September in 2025.

The gross profit of Johnson & Johnson with headquarters in the United States amounted to ***** billion U.S. dollars in 2024. The reported fiscal year ends on December 29.Compared to the earliest depicted value from 2020 this is a total increase by approximately **** billion U.S. dollars. The trend from 2020 to 2024 shows, furthermore, that this increase happened continuously.

The net income of Johnson Matthey with headquarters in the United Kingdom amounted to ************ British pounds in 2023. The reported fiscal year ends on March 31.Compared to the earliest depicted value from 2019 this is a total decrease of approximately ************ British pounds. The trend from 2019 to 2023 shows, however, that this decrease did not happen continuously.

Net-Income-From-Continuing-Operations Time Series for Johnson Health Tech Co Ltd. Johnson Health Tech. Co., Ltd. engages in the manufacture and sale of sports and fitness equipment in the Americas, Europe, Asia, and internationally. It offers Cardiopulmonary resuscitation and weight training equipment, and related electronic components, as well as video transmission and streaming service; researches, develops, manufactures, and trades in massage chairs; and sells food products. The company was incorporated in 1975 and is based in Taichung City, Taiwan.

J&J reported 138.1K in Employees for its fiscal year ending in December of 2024. Data for J&J | JNJ - Employees Total Number including historical, tables and charts were last updated by Trading Economics this last September in 2025.

Introduction

Johnson & Johnson Statistics: Johnson & Johnson (J&J) is a global leader in healthcare, offering a wide range of products in pharmaceuticals, medical devices, and consumer health. In 2024, it will continue to maintain its position as a powerhouse in the healthcare sector, driven by innovation, strategic acquisitions, and a strong commitment to sustainability. This article has covered all essential analyses of the platform's current trends from different insights and will guide you accordingly.